Pharmacology In Drug Discovery And Development -

Once a chemical “hit” is found, pharmacology drives refinement.

Perhaps the single most important concept in drug development is the Therapeutic Index (TI) : the ratio of the toxic dose to the therapeutic dose.

Pharmacology aims to engineer a TI >10 for chronic diseases. Oncology is the exception—cytotoxic chemotherapies often have TIs close to 1, accepted due to disease severity. pharmacology in drug discovery and development

This phase is primarily about safety and pharmacokinetics. Healthy volunteers are given the drug to see how the human body processes it.

The journey begins with "Target Identification." Pharmacologists work to understand the underlying biology of a disease. For example, if a specific receptor is overactive in cancer cells, that receptor becomes the "target." Once a chemical “hit” is found, pharmacology drives

Once a target is identified, the search for a molecule that can interact with it begins. This is where High-Throughput Screening (HTS) comes in. Pharmacologists test thousands of compounds to see which ones bind to the target.

However, finding a compound that binds isn't enough. This is where the "Hit-to-Lead" phase occurs, driven by pharmacological data: In vivo pharmacology:

The future of pharmacology is personalized. Genetic variants in CYP2C19 (affecting clopidogrel activation) or HLA-B*5701 (abacavir hypersensitivity) are now pre-screened. Regulatory agencies now encourage or mandate pharmacogenomic labeling. Discovery teams are designing "companion diagnostics" alongside drugs to identify responders.

Pharmacology determines how a drug enters the bloodstream. Is it orally bioavailable? Does it survive stomach acid? Do gut transporters like P-glycoprotein pump it back into the lumen? Modern drug discovery uses high-throughput Caco-2 cell assays (mimicking human intestinal epithelium) to predict absorption before animal studies.

This is perhaps the most critical hurdle. Pharmacologists conduct acute and chronic toxicity studies in animal models. They look for damage to major organs (liver, kidneys, heart) and determine the "No Observed Adverse Effect Level" (NOAEL). This data sets the starting dose for human trials.

In this phase, pharmacokinetics takes center stage. A drug might work in a petri dish, but can it survive the acidic environment of the stomach? Will it cross the blood-brain barrier?